Beeson (1946) first defined endotoxin tolerance as a reduced endotoxin-induced fever following repeated injections of typhoid vaccine. Freudenberg and Galanos (1988) demonstrated that endotoxin tolerance that can protect against a lethal challenge of lipopolysaccharide (LPS) involves the participation of macrophages. Evans and Zuckerman (1991) reported a role for glucocorticoids in endotoxin tolerance. Prostaglandins, interleukin-(IL-)10, and transforming growth factor-β are other players of in vivo endotoxin tolerance. Dramatic reduction of plasma tumor necrosis factor (TNF) (Mathison et al. 1990) and other cytokines in response to LPS parallels endotoxin tolerance. The reduced capacity to produce TNF and other cytokines can be mimicked in vitro by pretreatment of monocytes or macrophages with LPS. It is not a specific phenomenon and can be induced by other agents or events. Cross-tolerance between LPS, TLR2 specific ligands, IL-1 and TNF has been regularly reported. A similar loss of LPS-reactivity has been repeatedly reported in leukocytes of septic patients and in patients with non-infectious systemic inflammation response syndrome (SIRS; e.g . surgery, trauma, cardiac arrest and resuscitation, etc.). Studies on cellular signaling within leukocytes from septic and SIRS patients reveal numerous alterations of the activation pathways reminiscent of those observed in endotoxin-tolerant cells. While endotoxin tolerance prevents severity of infections and ischemia-reperfusion damage, it has been suggested that the immune dysregulation observed in SIRS patients was associated with an enhanced sensitivity to nosocomial infections. In conclusion, in vitro and in vivo endotoxin tolerance, either experimental or due to clinical status, are similar but not identical.
References
1.
Cross ASEndotoxin tolerance — current concepts in historical perspective . J Endotoxin Res2002; 8: 83—98.
2.
Beeson PBDevelopment of tolerance to typhoid bacterial pyrogen and its abolition by reticulo-endothelial blockade. Proc Soc Exp Biol Med1946; 61: 248—250.
3.
Freeman HHPassive transfer of tolerance to pyrogenicity of bacterial endotoxin . J Exp Med1960; 111: 453—463.
4.
Greisman SE, Hornick RB, Wagner Jr HN, Woodward WE, Woodward TEThe role of endotoxin during typhoid fever and tularemia in man. J Clin Invest1969; 48: 613—629.
5.
Rubenstein M. , Mulholland JH, Jeffery GM, Wolf SMMalaria induced endotoxin tolerance. Proc Soc Exp Biol Med1965; 118: 283—287.
6.
McCabe WREndotoxin tolerance. II. Its occurence in patients with pyelonephritis . J Clin Invest1963; 42: 618—625.
7.
Neva FA, Morgan HRTolerance to the action of endotoxin of enteric bacilli in patients convalescent from typhoid and paratyphoid fevers. J Lab Clin Med1950; 35: 911—922.
8.
Heyman A., Beeson PBInfluence of various disease states upon the febrile response to intravenous injection of typhoid bacterial pyrogen. J Lab Clin Med1949; 34: 1400—1403.
9.
Watson DW, Kim YBModification of host responses to bacterial endotoxins. I. Specificity of pyrogenic tolerance and the role of hypersensitivity in pyrogenicity, lethality and skin reactivity. J Exp Med1963; 118: 425—446.
10.
Freudenberg MA, Galanos C.Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages . Infect Immun1988; 56: 1352—1357.
11.
He W., Fong Y., Marano MA et al. Tolerance to endotoxin prevents mortality in infected thermal injury: association with attenuated cytokine responses. J Infect Dis1992; 165: 859—864.
Heemann U., Szabo A., Hamar P. et al. Lipopolysaccharide pretreatment protects from renal ischemia/reperfusion injury. Possible connection to an interleukin-6 dependent pathway. Am J Pathol2000; 156: 287—293.
14.
Eising GP, Mao L., Schmid-Schonbein GW, Engler RL, Ross J.Effects of induced tolerance to bacterial lipopolysaccharide on myocardial infarct size in rats. Cardiovasc Res1996; 31: 73—81.
15.
Ackerman M., Reuter M., Flohé S., Bahrami S., Redl H., Schade FUCytokine synthesis in the liver of endotoxin-tolerant and normal rats during hemorrhagic shock. J Endotoxin Res2001; 7: 105—112.
16.
Youngner JS, Stinebring WRInterferon appearance stimulated by endotoxin bacteria or viruses in mice pre-treated with Escherichia coli endotoxin or infected with Mycobacterium tuberculosis. Nature1965; 208: 456—458.
17.
Severn A., Xu D., Doyle J. et al. Pre-exposure of murine macrophages to lipopolysaccharide inhibits the induction of nitric oxide synthase and reduces leishmanicidal activity . Eur J Immunol1993; 23: 1711—1714.
18.
Mason CM, Dobard E., Summer WR, Nelson S.Intraportal lipopolysaccharide suppresses pulmonary antibacterial defense mechanisms. J Infect Dis1997; 176: 1293—1302.
19.
Rayhane N., Fitting C., Lortholary O., Dromer F., Cavaillon J-M.Administration of endotoxin associated with lipopolysaccharide tolerance protects mice against fungal infection. Infect Immun2000; 68: 3748—3753.
Mathison JC , Virca GD, Wolfson E., Tobias PS, Glaser K., Ulevitch RJAdaptation to bacterial lipopolysaccharide controls lipopolysaccharide-induced tumor necrosis factor production in rabbit macrophages. J Clin Invest1990; 85: 1108—1118.
22.
Rayhane N., Fitting C., Cavaillon J-M.Dissociation of INF-γ from IL-12 and IL-18 during endotoxin tolerance . J Endotoxin Res1999; 5: 319—324.
23.
Astiz ME, Rackow EC, Still JG et al. Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective double blind, randomized, controlled trial. Crit Care Med1995; 23: 9—17.
24.
Virca GD, Kim SY, Glaser KB, Ulevitch RJLipopolysaccharide induces hyporesponsiveness to its own action in RAW 264.7 cells. JBiol Chem1989; 264: 21951—21956.
Matic M., Simon SRTumor necrosis factor release from lipopolysaccharide-stimulated human monocytes: lipopolysaccharide tolerance in vitro. Cytokine1991; 3: 576—583.
27.
Muñoz C., Carlet J., Fitting C., Misset B., Bleriot JP, Cavaillon JMDysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest1991; 88: 1747—1754.
28.
Ertel W., Keel M., Neidhardt R. et al. Inhibition of the defense system stimulating interleukin-12 interferon-γ pathway during critical illness. Blood1997; 89: 1612—1620.
29.
Randow F., Syrbe U., Meisel C. et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor β. J Exp Med1995; 181: 1887—1892.
30.
Van Deuren M., Van Der Ven-Jongekrijg H., Demacker Pnm et al. Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis1994; 169: 157—161.
31.
Granowitz EV , Porat R., Mier JW et al. Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans . J Immunol1993; 151: 1637—1645.
32.
McCall CE, Grosso-Wilmoth LM, LaRue K., Guzman RN, Cousart SLTolerance to endotoxin-induced expression of the interleukin-1β gene in blood neutrophils of humans with the sepsis syndrome. J Clin Invest1993; 91: 853—861.
33.
Marie C., Muret J., Fitting C., Losser M-R., Payen D., Cavaillon J-M.Reduced ex vivo interleukin-8 production by neutrophils in septic and non-septic systemic inflammatory response syndrome. Blood1998; 91: 3439—3446.
34.
Marie C., Muret J., Fitting C., Payen D., Cavaillon J-M.IL-1 receptor antagonist production during infectious and noninfectious systemic inflammatory response syndrome. Crit Care Med2000; 28: 2277—2283.
35.
Evans GF, Zuckerman SHGlucocorticoid-dependent and independent mechanisms involved in lipopolysaccharide tolerance. Eur J Immunol1991; 21: 1973—1979.
36.
Annane D., Sebille V., Troche G., Raphael JC, Gajdos P., Bellissant E.A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA2000; 283: 1038—1045.
37.
Cavaillon J-M. , Pitton C., Fitting C.Endotoxin tolerance is not a LPS-specific phenomenon: partial mimicry with IL-1, IL-10 and TGFβ . J Endotoxin Res1994; 1: 21—29.
38.
Berg D., Kühn R., Rajewsky K. et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxin shock and the Schwartzman reaction but not endotoxin tolerance. J Clin Invest1995; 96: 2339—2347.
39.
Marchant A. , Alegre M., Hakim A. et al. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol1995; 15: 265—272.
40.
Brandtzaeg P., Osnes L., vstebø R., Joø GB, Westwik AB, Kierulf P.Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med1996; 184: 51—60.
41.
Marie C., Fitting C., Muret J., Payen D., Cavaillon J-M.Interleukin-8 production in whole blood assays: is interleukin-10 responsible for the downregulation observed in sepsis? Cytokine2000; 12: 55—61.
42.
Adrie C., Adib-Conquy M., Laurent I. et al. Successful cardiopulmonary resuscitation after cardiac arrest as a `sepsis like' syndrome. Circulation2002 ; 106: 562—568.
43.
Kitchens RL , Thompson PA, Viriyakosol S., O'Keefe GE, Munford RSPlasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins . J Clin Invest2001; 108: 485—493.
44.
Vreugdenhil Ace, Snoeck Amp, van't Veer C., Greve Jwm, Buurman WALPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction . J Clin Invest2001; 107: 225—234.
45.
Cavaillon J-M. , Fitting C., Haeffner-Cavaillon N., Kirsch SJ, Warren HSCytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide . Infect Immun1990; 58: 2375—2382.
46.
Warren HS, Knights CV, Siber GRNeutralization and lipoprotein binding of lipopolysaccharides in tolerant rabbit serum. J Infect Dis1986; 154: 784—791.
47.
Haas JG, Meyer N., Riethmüller G., Ziegler-Heitbrock Hwl.Inhibition of lipopolysaccharide-induced in vitro desensitization by interferon-γ . Eur J Immunol1990; 20: 1181—1184.
48.
Randow F., Döcke WD, Bundschuh DS, Hartung T., Wendel A., Volk HDIn vitro prevention and reversal of lipopolysaccharide desensitization by IFN-γ, IL-12 and GM-CSF. J Immunol1997 ; 158: 2911—2918.
49.
Adib-Conquy M. , Cavaillon J-M.IFN-γ and GM-CSF prevent endotoxin tolerance in human monocytes by promoting IRAK expression and its association to MyD88, and not by modulating TLR4 expression. J Biol Chem2002; 277: 27927—27934.
50.
BundschuhDS, Barsig J., Hartung T. et al. Granulocyte-macrophage colony-stimulating factor and IFN-gamma restore the systemic TNFalpha response to endotoxin in lipopolysaccharide-desensitized mice. J Immunol1997; 158: 2862—2871.
51.
Mackensen A. , Galanos C., Engelhardt R.Modulating activity of interferon-γ on endotoxin-induced cytokine production in cancer patients. Blood1991; 78: 3254—3258.
52.
Döcke WD, Randow F., Syrbe U. et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med1997; 3: 678—681.
53.
Medvedev AE, Henneke P., Schromm A. et al. Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J Immunol2001 ; 167: 2257—2267.
54.
Hajishengallis G., Martin MC, Sojar HT et al. Dependence of bacterial protein adhesins on Toll-like receptors for proinflammatory cytokine induction. Clin Diagn Lab Immunol2002; 9: 403—411.
55.
Burkart V., Kim YE, Ghiea I. et al. Cholera toxin B pretreatment of macrophages and monocytes diminishes their proinflammatory responsiveness to lipopolysaccharide. J Immunol2002; 168: 1730—1737.
56.
Lehner MD, Morath S., Michelsen KS, Schumann RR, Hartung T.Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators . J Immunol2001; 166: 5161—5167.
57.
Cabié A., Fitting C., Farkas J.-C et al. Influence of surgery on in-vitro cytokine production by human monocytes. Cytokine1992; 4: 576—580.
58.
Astiz M., Saha D., Lustbader D., Lin R., Rackow E.Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis. J Lab Clin Med1996; 128: 597—600.
59.
Cavaillon J-M. , Muñoz C., Marty C., Cabié A., Tamion F., Misset B., Carlet J., Fitting C.Cytokine production by monocytes from patients with sepsis syndrome and by endotoxin-tolerant monocytes. In: Levin J, Alving CR, Munford RS, Stütz PL. (eds) Bacterial Endotoxin: Recognition and Effector Mechanisms. Amsterdam: Elsevier, 1993; 275—284.
60.
Wilhelm W., Grundmann U., Rensing H. et al. Monocyte deactivation in severe human sepsis or following cardiopulmonary bypass. Shock2002; 17: 354—360.
61.
Schultz MJ, Olszyna DP, de Jonge E., Verbon A., van Deventer Sjh, van der Poll T.Reduced ex vivo chemokine production by polymorphonuclear cells after in vivo exposure of normal humans to endotoxin. J Infect Dis2000; 182: 1264—1267.
62.
Mitov IG, Kropec A., Benzing A. et al. Differential cytokine production in stimulated blood cultures from intensive care patients with bacterial infections. Infection1997; 25: 206—212.
63.
Adib-Conquy M., Moine P., Asehnoune K. et al. Toll-like receptor (TLR) 2-, TLR4- and TLR9-mediated TNF and IL-10 production differ during systemic inflammation. Submitted.
64.
Fraker DL, Stovroff MC, Merino MJ, Norton JATolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J Exp Med1988; 168: 95—105.
65.
Klir JJ, McClellan JL, Kozak W., Szelényi Z., Wong Ghw, Kluger MJSystemic but not central administration of tumor necrosis factor-α attenuates LPS induced fever in rats. Am J Physiol1995 ; 268: R480—R486.
66.
Ogle CK, Guo X., Chance WT, Ogle JDInduction of endotoxin tolerance in rat bone marrow cells by in vivo infusion of tumor necrosis factor. Crit Care Med1997 ; 25: 827—833.
67.
Henricson BE , Neta R., Vogel SNAn interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance. Infect Immun1991 ; 59: 1188—1191.
68.
Ferlito M., Romanenko OG, Ashton S., Squadrito F., Halushka PV, Cook JAEffect of cross-tolerance between endotoxin and TNFα or IL-1β on cellular signaling and mediator production. J Leukoc Biol2001; 70: 821—829.
69.
Blackwell TS , Blackwell TR, Christman JWImpaired activation of nuclear factor-kappaB in endotoxin-tolerant rats is associated with down-regulation of chemokine gene expression and inhibition of neutrophilic lung inflammation . J Immunol1997; 158: 5934—5940.
70.
Ziegler-Heitbrock Hwl, Wedel A., Schraut W. et al. Tolerance to lipopolysaccharide involves mobilization of nuclear factor κB with predominance of p50 homodimers . J Biol Chem1994; 269: 17001—17004.
71.
Adib-Conquy M., Adrie C., Moine P. et al. NF-κB expression in mononuclear cells of septic patients resembles that observed in LPS-tolerance . Am J Respir Crit Care Med2000; 162: 1877—1883.
72.
Adib-Conquy M., Asehnoune K., Moine P., Cavaillon J-M.Long-term impaired expression of nuclear factor-κB and IκBα in peripheral blood mononuclear cells of patients with major trauma. J Leukoc Biol2001; 70: 30—38.
73.
Learn CA, Boger MS, Li L., McCall CE. The phosphatidylinositol 3 kinase pathway selectively controls sIL-1ra not interleukin-1β production in the septic leukocyte. J Biol Chem2001; 276: 20234—20239.
74.
West MA, Heagy W.Endotoxin tolerance: a review. Crit Care Med2002; 30 (Suppl 1): S64—S73.
